Propanc Biopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | $3.5M | $-5.4M | — |
| FY2018 | $4.7M | $-6.8M | — |
| FY2019 | $1.7M | $-4.3M | — |
| FY2020 | $1.6M | $-3.6M | $67.0K |
| FY2021 | $624.6K | $-3.1M | $2.3K |
| FY2022 | $926.4K | $-3.0M | $4.1K |
| FY2023 | $390.5K | $-3.1M | — |
| FY2024 | $399.3K | $-3.8M | — |
| FY2025 | $537.9K | $13.9M | — |
| FY2026 | — | $9.4M | — |